Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Harohalli Shashidhar & Vasundhara Tolia. (2013) Esophagitis in children: an update on current pharmacotherapy. Expert Opinion on Pharmacotherapy 14:18, pages 2475-2487.
Read now
Read now
Nils-Olov Stålhammar, Brennan M Spiegel, Helena Granstedt Löfman, Maria Karlsson, Peter Wahlqvist, Jørgen Næsdal, M Todd Nelson & Nicolas Despiégel. (2012) Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA. Pragmatic and Observational Research 3, pages 57-67.
Read now
Read now
Javier P. Gisbert, Alun Cooper, Dimitrios Karagiannis, Jan Hatlebakk, Lars Agréus, Helmut Jablonowski & Monica Tafalla. (2009) Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. European Journal of General Practice 15:3, pages 154-160.
Read now
Read now
Philippe Ducrotté & Harley R. Liker. (2007) How do people with gastro-oesophageal reflux disease perceive their disease≟ Results of a multinational survey. Current Medical Research and Opinion 23:11, pages 2857-2865.
Read now
Read now
Articles from other publishers (42)
David Armstrong, Sachin Srinivasan, Ceciel Rooker, Paul Sinclair, Emily Taylor & Prateek Sharma. (2023) Symptom Profile, Proton Pump Inhibitor Therapy, and Diagnostic Testing in Patients With Persistent Reflux-Like Symptoms: Results From a Population-Based Survey. Foregut: The Journal of the American Foregut Society, pages 263451612311736.
Crossref
Crossref
R. Radha & R. Gopalakrishnan. 2022. Fundamentals and Methods of Machine and Deep Learning. Fundamentals and Methods of Machine and Deep Learning
135
152
.
Matthew H. Secrest, Robert W. Platt, Colin R. Dormuth, Dan Chateau, Laura Targownik, Rui Nie, Carla M. Doyle, Sophie Dell'Aniello & Kristian B. Filion. (2019) Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety 29:S1, pages 26-34.
Crossref
Crossref
Scott Klenzak, Igor Danelisen, Grace D Brannan, Melissa A Holland & Miranda AL van Tilburg. (2018) Management of gastroesophageal reflux disease: Patient and physician communication challenges and shared decision making. World Journal of Clinical Cases 6:15, pages 892-900.
Crossref
Crossref
Hong Joo Kim, Chang-Il Kwon, William R. Kessler, Don J. Selzer, Gail McNulty, Amol Bapaye, Luigi Bonavina & Glen A. Lehman. (2015) Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE? endoscopic stapling device. Surgical Endoscopy 30:8, pages 3402-3408.
Crossref
Crossref
Andreas Hallan, Maria Bomme, Kristian Hveem, Jane Møller-Hansen & Eivind Ness-Jensen. (2015) Risk Factors on the Development of New-Onset Gastroesophageal Reflux Symptoms. A Population-Based Prospective Cohort Study: The HUNT Study. American Journal of Gastroenterology 110:3, pages 393-400.
Crossref
Crossref
Motoyasu Kusano, Hiroko Hosaka, Osamu Kawamura, Akiyo Kawada, Shiko Kuribayashi, Yasuyuki Shimoyama, Hidetoshi Yasuoka, Masafumi Mizuide, Taku Tomizawa, Toshihiko Sagawa, Ken Sato & Masanobu Yamada. (2014) More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. Journal of Gastroenterology 50:3, pages 298-304.
Crossref
Crossref
Martin Wehling. 2015. Principles of Translational Science in Medicine. Principles of Translational Science in Medicine
107
113
.
Merel M Tielemans & Martijn GH van Oijen. (2013) Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study. BMC Gastroenterology 13:1.
Crossref
Crossref
N. B. Vakil, F. J. Huff & K. C. Cundy. (2013) Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease - insights into study design for transient lower sphincter relaxation inhibitors. Alimentary Pharmacology & Therapeutics 38:2, pages 107-117.
Crossref
Crossref
P. Moayyedi, R. Hunt, D. Armstrong, Y. Lei, M. Bukoski & R. White. (2013) The impact of intensifying acid suppression on sleep disturbance related to gastro‐oesophageal reflux disease in primary care. Alimentary Pharmacology & Therapeutics 37:7, pages 730-737.
Crossref
Crossref
Sylvester Chuks Nwokediuko. (2012) Current Trends in the Management of Gastroesophageal Reflux Disease: A Review. ISRN Gastroenterology 2012, pages 1-11.
Crossref
Crossref
A. Pali S. Hungin, Catherine Hill, Michael Molloy–Bland & Anan Raghunath. (2012) Systematic Review: Patterns of Proton Pump Inhibitor Use and Adherence in Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology 10:2, pages 109-116.
Crossref
Crossref
Per G Farup, Ivar Blix, Sigurd Førre, Gjermund Johnsen, Ove Lange, Rune Johannessen & Hermod Petersen. (2011) What causes treatment failure - the patient, primary care, secondary care or inadequate interaction in the health services?. BMC Health Services Research 11:1.
Crossref
Crossref
Etienne Dorval, Jean-Francois Rey, Christine Soufflet, Katarina Halling & Philippe Barthélemy. (2011) Perspectives on gastroesophageal reflux disease in primary care: the REFLEX study of patient-physician agreement. BMC Gastroenterology 11:1.
Crossref
Crossref
David Armstrong & Daniel Sifrim. (2011) New Pharmacologic Approaches in Gastroesophageal Reflux Disease. Thoracic Surgery Clinics 21:4, pages 557-574.
Crossref
Crossref
Gerald Holtmann, Marc-André Bigard, Peter Malfertheiner & Roy Pounder. (2011) Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. International Journal of Clinical Pharmacy 33:3, pages 493-500.
Crossref
Crossref
Stanislas Bruley des Varannes, Emmanuel Coron & Jean-Paul Galmiche. (2010) Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?. Best Practice & Research Clinical Gastroenterology 24:6, pages 905-921.
Crossref
Crossref
David Armstrong & Daniel Sifrim. (2010) New Pharmacologic Approaches in Gastroesophageal Reflux Disease. Gastroenterology Clinics of North America 39:3, pages 393-418.
Crossref
Crossref
Samira Toghanian, Peter Wahlqvist, David A. Johnson, Susan C. Bolge & Bengt Liljas. (2010) The Burden of Disrupting Gastro-Oesophageal Reflux Disease. Clinical Drug Investigation 30:3, pages 167-178.
Crossref
Crossref
Anders Lehmann, J?rgen M. Jensen & Guy E. Boeckxstaens. 2010. GABABReceptor Pharmacology - A Tribute to Norman Bowery. GABABReceptor Pharmacology - A Tribute to Norman Bowery
287
313
.
Robert J. Hoogendoorn, Lex Groeneveld & J. Andy Kwee. (2009) Patient Satisfaction with Switching to Esomeprazole from Existing Proton Pump Inhibitor Therapy for Gastro-Oesophageal Reflux Disease. Clinical Drug Investigation 29:12, pages 803-810.
Crossref
Crossref
Javier P Gisbert, Alun Cooper, Dimitrios Karagiannis, Jan Hatlebakk, Lars Agréus, Helmut Jablonowski & Javier Zapardiel. (2009) Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health and Quality of Life Outcomes 7:1.
Crossref
Crossref
Jane Møller Hansen, Mette Wildner-Christensen & Ove B Schaffalitzky de Muckadell. (2009) Gastroesophageal Reflux Symptoms in a Danish Population: A Prospective Follow-Up Analysis of Symptoms, Quality of Life, and Health-Care Use. The American Journal of Gastroenterology 104:10, pages 2394-2403.
Crossref
Crossref
A. P. S. HUNGIN, C. HILL & A. RAGHUNATH. (2009) Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Alimentary Pharmacology & Therapeutics 30:4, pages 331-342.
Crossref
Crossref
Stéphane Mouly, Agnès Charlemagne, Philippe Lejeunne & Francis Fagnani. (2009) Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution. Current Therapeutic Research 70:4, pages 282-298.
Crossref
Crossref
Martin Wehling. (2009) Assessing the translatability of drug projects: what needs to be scored to predict success?. Nature Reviews Drug Discovery 8:7, pages 541-546.
Crossref
Crossref
H. EL-SERAG, C. HILL & R. JONES. (2009) Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Alimentary Pharmacology & Therapeutics 29:5, pages 470-480.
Crossref
Crossref
Mark Bamford. 2009. Progress in Medicinal Chemistry Volume 47. Progress in Medicinal Chemistry Volume 47
75
162
.
Luis A. García Rodríguez, Ana Ruigómez, Elisa Martín-Merino, Saga Johansson & Mari-Ann Wallander. (2008) Relationship Between Gastroesophageal Reflux Disease and COPD in UK Primary Care. Chest 134:6, pages 1223-1230.
Crossref
Crossref
A. King, C. MacDonald & C. Örn. (2008) Understanding gastro-oesophageal reflux disease: a patient-cluster analysis. International Journal of Clinical Practice 62:12, pages 1838-1843.
Crossref
Crossref
R. Jones & T. Patrikios. (2008) The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. International Journal of Clinical Practice 62:12, pages 1844-1850.
Crossref
Crossref
J.-F. Bretagne, C. Honnorat, B. Richard-Molard, C. Soufflet & P. Barth?lemy. (2008) Management of gastroesophageal reflux disease by primary care physicians and gastroenterologists: A prospective study of patients? records. Gastroent?rologie Clinique et Biologique 32:12, pages 995-1000.
Crossref
Crossref
David Armstrong & Norma Marchetti. (2008) Pharmacist-specific guidelines for the medical management of GERD in adults*. Canadian Pharmacists Journal 141:sp1, pages S10-S15.e3.
Crossref
Crossref
D. ARMSTRONG. (2008) Systematic review: persistence and severity in gastroesophageal reflux disease. Alimentary Pharmacology & Therapeutics.
Crossref
Crossref
Gareth J. Sanger & Kevin Lee. (2008) Hormones of the gut–brain axis as targets for the treatment of upper gastrointestinal disorders. Nature Reviews Drug Discovery 7:3, pages 241-254.
Crossref
Crossref
Christina Reimer & Peter Bytzer. (2007) Perceptions and Beliefs concerning Gastroesophageal Reflux Disease: Physicians and Patients Disagree. Digestion 76:3-4, pages 229-234.
Crossref
Crossref
Lucía C. Fry, Klaus Mönkemüller & Peter Malfertheiner. (2007) Systematic review: endoluminal therapy for gastro-oesophageal reflux disease: evidence from clinical trials. European Journal of Gastroenterology & Hepatology 19:12, pages 1125-1139.
Crossref
Crossref
Emmanuel Coron, Jan G Hatlebakk & Jean-Paul Galmiche. (2007) Medical therapy of gastroesophageal reflux disease. Current Opinion in Internal Medicine 6:5, pages 467-472.
Crossref
Crossref
R. Jones, H. R. Liker & P. Ducrotté. (2007) Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. International Journal of Clinical Practice 61:8, pages 1301-1307.
Crossref
Crossref
Paul Moayyedi. (2007) Who Pays the Piper?. Journal of Clinical Gastroenterology 41:Supplement 2, pages S97-S101.
Crossref
Crossref
Andreas Leodolter & Roberto Penagini. (2007) On-Demand Therapy Is a Valid Strategy in GERD Patients: Pros and Cons. Digestive Diseases 25:3, pages 175-178.
Crossref
Crossref